Malcolm Macleod, who helped develop these best practices, tells The Scientist how the new guidelines for manuscript publishing seek to support a push for transparent and thorough sharing of methods and data.
The issue’s guest editors resign after falling out with the publisher over the management of papers, including a rejected manuscript on ivermectin, that were submitted for a special issue on drug repurposing for COVID-19.
The microbiome-testing company made misleading claims about its prospects and about its business strategy, which allegedly relied on fooling doctors into ordering unnecessary tests, according to the US government.
Current reporting about the contribution of genetic variations to a person’s risk of disease is often incomplete and hard to interpret, according to the authors of a set of best practices for presenting such information.
After refusing to pay the ransom demanded by those behind a cyberattack, the Netherlands Organisation for Scientific Research has been out of action since February 8.
The changes, which affect the declarations authors have to sign and the peer-review process, have received a mixed response from the scientific community.
The company behind a now-discredited study on hydroxychloroquine also posted a report that has been cited by Latin American governments recommending ivermectin as a possible coronavirus treatment. Clinicians there say the effects have been extremely damaging.
Our handbook on best practices for quality assurance in biomedicine can help funding agencies shore up research integrity—which is especially needed at a time when mistakes can have outsize effects.
The company had helped develop a tool to aid decision-making in distributing limited medical equipment among coronavirus patients, but two high-profile retractions call into question the validity of Surgisphere’s work in toto.
